Naltrexone Completed Phase 4 Trials for Schizophrenic Disorders / Alcohol Dependence / Schizoaffective Disorders / Bipolar Disorder (BD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00453804Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)
NCT00453609Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)
NCT00115037Managing Alcoholism in People Who Do Not Respond to Naltrexone
NCT00000450Naltrexone Maintenance Treatment of Alcoholism
NCT00000438Naltrexone Treatment for Alcoholism
NCT00000442Naltrexone for Relapse Prevention
NCT00000452Naltrexone Treatment of Alcohol Dependence
NCT00000455Naltrexone for Early Problem Drinkers
NCT00000456Behavioral Therapy Plus Naltrexone for Alcoholism
NCT00000445Use of Naltrexone in a Clinical Setting
NCT00000449Behavior and Naltrexone Treatment for Alcoholics
NCT00006449Post-Treatment Effects of Naltrexone
NCT00317031Individually Adapted Therapy of Alcoholism
NCT00006203Naltrexone, Craving, and Drinking
NCT00817089Understanding Treatment Response With Naltrexone Among White Alcoholics
NCT00920829Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism
NCT00223275Naltrexone for Bipolar Disorder and Alcohol Dependence
NCT00366626Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.
NCT00511836ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults
NCT00620750Extended-release Naltrexone for Alcohol Dependence in Primary Care
NCT00831272Pharmacogenetic Response to Naltrexone For Alcohol Dependence